Cannara Biotech Inc. (LOVFF) Comparison with companies in other sectors?

Cannara Biotech Inc. has a share price of 91.43M. You can analyze Cannara Biotech Inc. (LOVFF) competitors across different market sectors through stock heatmaps.

What are LOVFF's NET and operating margins?

Cannara Biotech Inc. (LOVFF) operating margin is around 0.20, and net profit margin is approximately 0.14 as of the latest reports.

In what way does LOVFF's earnings per share (EPS) trend reflect its financial momentum?

Cannara Biotech Inc. (LOVFF) EPS is 0.10 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Cannara Biotech Inc. is 13.14, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Cannara Biotech Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Cannara Biotech Inc. like P/E which is 12.18, P/B which is 1.73, and PEG which is 0.07. Compare them with sector averages to evaluate if the stock is priced fairly.

Cannara Biotech Inc.

LOVFF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$1.31

$-0.02(-1.24%)

Fundamental Analysis of Cannara Biotech Inc. (LOVFF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.10

P/E Ratio

13.14

ROE

0.15%

Net Margin

0.14%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$120.14M

Shares OutstandingTotal number of shares issued

$91.43M

Book Value/ShareNet worth per share

$1.04

Revenue/ShareAnnual revenue per share

$1.04

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.1

Net MarginNet income as percentage of revenue

14.22%

Operating MarginOperating income as percentage of revenue

19.85%

ROEReturn on shareholders' equity

15.12%

ROAReturn on total assets

8.30%

ROCEReturn on capital employed

14.46%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.05

Cash/ShareCash and equivalents per share

$0.06

FCF YieldFree cash flow as percentage of market cap

2.75%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for LOVFFFinancial Ratios Analysis details for LOVFF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for LOVFFSector Benchmarking details for LOVFF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Cannara Biotech Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Cannara Biotech Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Cannara Biotech Inc.'s unique business strengths and challenges.

Key Financial Metrics for Cannara Biotech Inc.

For Cannara Biotech Inc., essential financial indicators include EPS 0.10, PE 13.14, and ROE 0.15. These key ratios reveal insights into Cannara Biotech Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Cannara Biotech Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Cannara Biotech Inc.

Metrics like Net Margin 14.22% and ROA 8.30% shed light on how well Cannara Biotech Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Cannara Biotech Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Cannara Biotech Inc.

Using ratios such as P/B Ratio 1.73 and PEG Ratio 0.07, investors can assess whether Cannara Biotech Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Cannara Biotech Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Cannara Biotech Inc.

Financial health indicators, such as Debt/Equity Ratio 0.52 and Cash Flow $0.05, provide a snapshot of Cannara Biotech Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Cannara Biotech Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Cannara Biotech Inc.

Investing in Cannara Biotech Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Cannara Biotech Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;